天眼查商业履历信息显示，吉林省西点药业科技发展股份有限公司，成立于1990年，位于吉林市，是一 家以从事医药制造业为主的企业。企业注册资本7649.4685万人民币，实缴资本3080.9903万人民币。公 司法定代表人为张俊。 通过天眼查大数据分析，吉林省西点药业科技发展股份有限公司共对外投资了3家企业，参与招投标项 目345次，知识产权方面有商标信息42条，专利信息16条，此外企业还拥有行政许可83个。 来源：金融界 金融界消息 截至2025年8月25日收盘，西点药业（301130）报收于32.75元，上涨0.52%，换手率 5.25%，成交量3.07万手，成交金额1.01亿元。 资金流向方面，今日主力资金净流出1524.54万元，占比成交额15.14%。其中，超大单净流出1206.32万 元、占成交额11.98%，大单净流出318.22万元、占成交额3.16%，中单净流出流入862.63万元、占成交 额8.57%，小单净流入661.92万元、占成交额6.58%。 西点药业最新一期业绩显示，截至2025中报，公司营业总收入1.28亿元、同比减少0.51%，归属净利润 2494.46万元，同比增长2.02%， ...

Core Viewpoint - Wanze Co., Ltd. has shown positive financial performance with significant revenue and profit growth in the latest half-year report, indicating a strong operational capacity in the pharmaceutical manufacturing sector [1]. Financial Performance - As of the latest mid-year report, the company reported total revenue of 625 million yuan, representing a year-on-year growth of 24.40% [1]. - The net profit attributable to shareholders reached 119 million yuan, with a year-on-year increase of 21.84% [1]. - The company's net profit after deducting non-recurring gains and losses was 110 million yuan, reflecting a growth of 29.28% year-on-year [1]. - The liquidity ratios are as follows: current ratio at 1.278 and quick ratio at 0.854, indicating a stable liquidity position [1]. - The asset-liability ratio stands at 59.38%, suggesting a moderate level of financial leverage [1]. Market Activity - As of August 25, 2025, Wanze Co., Ltd. shares closed at 17.06 yuan, with an increase of 0.95% [1]. - The trading volume was 263,600 hands, with a total transaction value of 447 million yuan [1]. - The main capital flow indicated a net outflow of 13.35 million yuan, accounting for 2.99% of the transaction value [1]. - Large orders showed a net outflow of 33.45 million yuan, representing 7.48% of the transaction value, while large orders had a net inflow of 20.10 million yuan, accounting for 4.5% [1]. Company Background - Wanze Co., Ltd. was established in 1992 and is located in Shantou City, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of approximately 500.71 million yuan and a paid-in capital of 62 million yuan [1][2]. - The legal representative of the company is Huang Zhengguang [1].

金融界消息 截至2025年8月25日收盘，新开源（300109）报收于18.45元，上涨0.16%，换手率4.35%， 成交量19.56万手，成交金额3.61亿元。 资金流向方面，今日主力资金净流出1351.15万元，占比成交额3.74%。其中，超大单净流出160.84万 元、占成交额0.45%，大单净流出1190.31万元、占成交额3.29%，中单净流出流入340.53万元、占成交 额0.94%，小单净流入1010.61万元、占成交额2.8%。 新开源最新一期业绩显示，截至2025一季报，公司营业总收入3.25亿元、同比减少17.69%，归属净利润 8042.03万元，同比减少33.75%，扣非净利润6941.62万元，同比减少44.85%，流动比率2.565、速动比率 2.016、资产负债率18.03%。 通过天眼查大数据分析，博爱新开源医疗科技集团股份有限公司共对外投资了19家企业，参与招投标项 目34次，知识产权方面有商标信息56条，专利信息56条，此外企业还拥有行政许可95个。 来源：金融界 天眼查商业履历信息显示，博爱新开源医疗科技集团股份有限公司，成立于2003年，位于焦作市，是一 家以从事医药 ...

Group 1 - The core point of the article highlights the recent performance of Harbin Pharmaceutical Group Co., Ltd. (哈药股份), noting a stock price of 3.92 yuan, a decrease of 2.97% as of August 25, 2025 [1] - The company reported total revenue of 8.125 billion yuan for the first half of 2025, a year-on-year decrease of 0.21%, and a net profit attributable to shareholders of 260 million yuan, down 24.37% year-on-year [1] - The company's liquidity ratios include a current ratio of 1.440 and a quick ratio of 1.179, with a debt-to-asset ratio of 54.71% [1] Group 2 - Harbin Pharmaceutical Group has made investments in 30 companies and participated in 3,232 bidding projects [2] - The company holds 2 trademark registrations and 67 patents, along with 21 administrative licenses [2]

通过天眼查大数据分析，广誉远中药股份有限公司共对外投资了10家企业，参与招投标项目36次，专利 信息2条，此外企业还拥有行政许可3个。 来源：金融界 广誉远最新一期业绩显示，截至2025中报，公司营业总收入7.79亿元、同比增长18.14%，归属净利润 7685.71万元，同比增长28.95%，扣非净利润6799.86万元，同比增长21.76%，流动比率2.152、速动比率 1.242、资产负债率31.98%。 天眼查商业履历信息显示，广誉远中药股份有限公司，成立于1996年，位于晋中市，是一家以从事医药 制造业为主的企业。企业注册资本48949.1141万人民币，实缴资本7150.9万人民币。公司法定代表人为 李晓军。 金融界消息 截至2025年8月25日收盘，广誉远（600771）报收于21.48元，上涨0.75%，换手率4.13%， 成交量20.21万手，成交金额4.32亿元。 资金流向方面，今日主力资金净流出1262.29万元，占比成交额2.92%。其中，超大单净流出330.36万 元、占成交额0.77%，大单净流出931.93万元、占成交额2.16%，中单净流出流入302.32万元、占成交额 0.7 ...

Group 1 - The core viewpoint of the news is that Gansu Longshen Rongfa Pharmaceutical Co., Ltd. has reported a decrease in total operating revenue while showing an increase in net profit for the first half of 2025 [1] - As of August 25, 2025, the company's stock price closed at 10.97 yuan, down 0.99%, with a turnover rate of 6.15% and a trading volume of 185,600 hands, amounting to 203 million yuan [1] - The company's latest financial results show total operating revenue of 496 million yuan, a year-on-year decrease of 8.21%, while net profit attributable to shareholders reached 27.96 million yuan, a year-on-year increase of 27.48% [1] Group 2 - The company has a current ratio of 1.546, a quick ratio of 1.238, and a debt-to-asset ratio of 44.22% [1] - Gansu Longshen Rongfa has made investments in 5 enterprises and participated in 2,054 bidding projects [2] - The company holds 17 trademark registrations and 46 patents, along with 160 administrative licenses [2]

天眼查商业履历信息显示，奥精医疗科技股份有限公司，成立于2004年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本13555.1584万人民币，实缴资本13555.1584万人民币。公司法定代 表人为胡刚。 通过天眼查大数据分析，奥精医疗科技股份有限公司共对外投资了8家企业，参与招投标项目131次，知 识产权方面有商标信息48条，专利信息134条，此外企业还拥有行政许可21个。 来源：金融界 金融界消息 截至2025年8月25日收盘，奥精医疗（688613）报收于20.68元，下跌1.15%，换手率 3.59%，成交量4.92万手，成交金额1.03亿元。 资金流向方面，今日主力资金净流出1133.35万元，占比成交额11.05%。其中，超大单净流出610.54万 元、占成交额5.95%，大单净流出522.81万元、占成交额5.1%，中单净流出流入523.69万元、占成交额 5.11%，小单净流入609.66万元、占成交额5.94%。 奥精医疗最新一期业绩显示，截至2025一季报，公司营业总收入4245.97万元、同比减少10.35%，归属 净利润104.15万元，同比减少84.99%，扣非净利润 ...

Group 1 - The core viewpoint of the news is that Kunming Pharmaceutical Group Co., Ltd. has experienced a decline in revenue and net profit in its latest financial report, indicating potential challenges in its business performance [1][3] - As of August 25, 2025, the company's stock price closed at 14.48 yuan, with a slight increase of 0.63% and a trading volume of 30.55 million shares, amounting to a transaction value of 442 million yuan [1] - The company's total operating revenue for the first half of 2025 was 3.351 billion yuan, a year-on-year decrease of 11.68%, while the net profit attributable to shareholders was 198 million yuan, down 26.88% year-on-year [1] Group 2 - Kunming Pharmaceutical Group has made investments in 45 companies and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 222 trademark registrations and 465 patents, indicating a strong focus on intellectual property [2] - Additionally, the company possesses 355 administrative licenses, reflecting its compliance and operational capabilities [2]

天眼查商业履历信息显示，申联生物医药(上海)股份有限公司，成立于2001年，位于上海市，是一家以 从事医药制造业为主的企业。企业注册资本41064.4万人民币，实缴资本31689.7548万人民币。公司法定 代表人为聂东升。 通过天眼查大数据分析，申联生物医药(上海)股份有限公司共对外投资了7家企业，参与招投标项目 1618次，知识产权方面有商标信息31条，专利信息143条，此外企业还拥有行政许可53个。 来源：金融界 金融界消息 截至2025年8月25日收盘，申联生物（688098）报收于14.5元，上涨13.81%，换手率 12.69%，成交量52.10万手，成交金额7.23亿元。 资金流向方面，今日主力资金净流入3539.32万元，占比成交额4.9%。其中，超大单净流出1070.38万 元、占成交额1.48%，大单净流入4609.70万元、占成交额6.38%，中单净流出流入3943.95万元、占成交 额5.46%，小单净流出7483.27万元、占成交额10.35%。 申联生物最新一期业绩显示，截至2025一季报，公司营业总收入7874.11万元、同比减少10.58%，归属 净利润301.99万元，同比减 ...

恒瑞医药最新一期业绩显示，截至2025中报，公司营业总收入157.61亿元、同比增长15.88%，归属净利 润44.50亿元，同比增长29.67%，扣非净利润42.73亿元，同比增长22.43%，流动比率13.495、速动比率 12.750、资产负债率6.14%。 天眼查商业履历信息显示，江苏恒瑞医药股份有限公司，成立于1997年，位于连云港市，是一家以从事 医药制造业为主的企业。企业注册资本637900.2274万人民币，实缴资本6190万人民币。公司法定代表 人为孙飘扬。 资金流向方面，今日主力资金净流入1.92亿元，占比成交额3.46%。其中，超大单净流入4.38亿元、占 成交额7.9%，大单净流出24641.35万元、占成交额4.44%，中单净流出流出5440.84万元、占成交额 0.98%，小单净流出13757.55万元、占成交额2.48%。 金融界消息 截至2025年8月25日收盘，恒瑞医药（600276）报收于66.26元，上涨1.97%，换手率 1.33%，成交量84.92万手，成交金额55.52亿元。 通过天眼查大数据分析，江苏恒瑞医药股份有限公司共对外投资了37家企业，参与招投标项目500 ...